Skip to content

Onxeo: Q1 2017 financial information and business update

  • Revenues up 55% to €1.2 million
  • Cash position of €21.7 million at March 31, 2017
  • All strategic assets are progressing according to development plans

Paris, April 26, 2017 – 6.30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announces its consolidated revenues and cash position at March 31, 2017 and issues a business update.

Judith Greciet, Chief Executive Officer of Onxeo, says: “Our achievements over the first quarter of 2017 are perfectly aligned with our strategy that aims to position Onxeo as a major reference in orphan oncology diseases. We are particularly pleased to have been able to finalize enrollment in the ReLive phase III study of Livatag® in January, in line with our goal to obtain preliminary clinical results around mid-year. Besides, we have made significant progress in our efforts to develop our other two strategic assets, Beleodaq® administered orally and AsiDNA™, which should enable the initiation of phase I clinical trials on these two promising compounds by the end of 2017. All indicators are positive at the end of the first quarter and in line with our business plan.

Please find the full press release on this link. Onxeo_Q1_2017

About Onxeo

Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications.   The Company is headquartered in Paris, France with offices in Denmark and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).

Learn more by visiting


This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the 2016 Reference Document filed with the AMF on April 24, 2017, which is available on the AMF website ( or on the company’s website (


Onxeo Valérie Leroy Investor Relations +33 1 45 58 76 00 Media Relations Caroline Carmagnol / Simon Derbanne -Alize RP  +33 6 64 18 99 59 / +33 6 38 16 26 41
Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh – NewCap +33 1 44 71 94 92 Investor Relations US Brian Ritchie – LifeSci Advisors +1 212 915 2578

Source: Onxeo